Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Lung Cancer Therapy Using Doxorubicin And Curcumin Combination: Targeted Prodrug Based, PH Sensitive Nanomedicine.
Y. Hong, S. Che, Beina Hui, Yunyi Yang, X. Wang, Xiaozhi Zhang, Yongqian Qiang, Hailin Ma
Published 2019 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Lung cancer is the leading cause of cancer death worldwide. To overcome the toxic side effects and multidrug resistance (MDR) during doxorubicin (DOX) chemotherapy, a urokinase plasminogen activator receptor (uPAR) targeting U11 peptide decorated, pH-sensitive, dual drugs co-encapsulated nanoparticles (NPs) system is employed in this study. A U11 peptide conjugated, pH-sensitive DOX prodrug (U11-DOX) was synthesized and used as materials to produce NPs. A curcumin (CUR) and U11-DOX co-encapsulated NPs system (U11-DOX/CUR NPs) was constructed to treat lung cancer. After the characterization of biophysical properties of this NPs system, synergistic chemotherapeutic efficacy was evaluated in both cultured cancer cells and tumor-bearing animal model. U11-DOX/CUR NPs had a uniformly spherical shape with a core-shell structure. The mean particle size and zeta potential of the U11-DOX/CUR NPs was 121.3 nm and -33.5 mV, with a DOX and CUR EE of 81.7 and 90.5%, respectively. The DOX release from U11-DOX/CUR NPs was 83.5, 55.2, and 32.8% correspondence to the pH of 5.0, 6.0 and 7.4. Cellular uptake efficiency of U11-DOX/CUR NPs was significantly higher than non U11 peptide decorated DOX/CUR NPs. U11-DOX/CUR NPs displayed a pronounced synergy effects in vitro and an obvious tumor tissue accumulation efficiency in vivo. In vivo antitumor experiment showed that U11-DOX/CUR NPs could inhibit the tumor growth to a level of 85%.In vitro and in vivo studies demonstrated that U11-DOX/CUR NPs is a sustained released, pH responsive, synergistic antitumor system. This study suggests that the U11-DOX/CUR NPs have promising potential for combination treatment of lung cancer.
This paper references
Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
P. Zhang (2015)
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
Lihong Mo (2015)
Lung Cancer Statistics.
L. Torre (2016)
Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Changming Li (2017)
Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation
J. Yu (2018)
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
H. Pappot (1997)
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
R. Zhang (2017)
Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
Matthew C. Ernst (2010)
Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance.
Z. Li (2018)
Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
S. Gunaseelan (2010)
Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers.
C. Cho (2001)
Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
B. Liu (2017)
pH-sensitive doxorubicin-conjugated prodrug micelles with charge-conversion for cancer therapy.
B. Ma (2018)
PEGylated nanoliposomes encapsulating angiogenic peptides improve perfusion defects: Radionuclide imaging-based study.
Hyosook Hwang (2016)
Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.
M. Wang (2009)
Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells
A. Srivastava (2016)
Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer.
Mingqiang Li (2014)
NO prodrug-conjugated, self-assembled, pH-responsive and galactose receptor targeted nanoparticles for co-delivery of nitric oxide and doxorubicin.
J. Zhang (2018)
The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small cell lung cancer
C. E. Almasi (2013)
Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft.
Kevin S. Chu (2013)
Natural products against cancer angiogenesis
El Bairi Khalid (2016)
Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans
Q. Zia (2015)
Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2.
H. Zhang (2015)
Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
E. Galbiati (2015)
Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer
Vendula Pospíchalová (2015)
Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats
J. Lee (2014)
Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA
Lekha Nair K (2011)
pH-sensitive polymeric micelles formed by doxorubicin conjugated prodrugs for co-delivery of doxorubicin and paclitaxel.
Yakun Ma (2016)
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
S. Jahan (2017)
Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin.
Shuang Li (2017)
Curcumin and lung cancer—a review
H. Mehta (2014)
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.
M. J. Ernsting (2013)
Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway
Yinxiang Lv (2017)
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
Xiao-qian Dou (2018)
Effects of pH-sensitive chain length on release of doxorubicin from mPEG-b-PH-b-PLLA nanoparticles
R. Liu (2012)
A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
X. Zhou (2015)
EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer
X. Zhang (2016)
A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy
R. Li (2014)
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy
Jicai Zhang (2018)
Dextran-b-poly(L-histidine) copolymer nanoparticles for ph-responsive drug delivery to tumor cells
Jong-ho Hwang (2013)
Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles.
Zizheng Song (2018)
Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer
Y. Zhang (2016)
Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy
Narsireddy Amreddy (2015)
High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile
R. Mukthavaram (2013)
Co -delivery of Sulforaphane and Curcumin with PEGylated Iron Oxide-Gold Core Shell Nanoparticles for Delivery to Breast Cancer Cell Line
H. Danafar (2018)
Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine
T. Santiago (2017)
Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Tongxing Cui (2017)
Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses
P. Siafaka (2016)
Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy.
M. O. Abdalla (2011)
Nanoparticles containing insoluble drug for cancer therapy.
S. Guo (2014)
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Jieke Yan (2017)
Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy
Shenwu Zhang (2017)
pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system
D. Chen (2012)
Role of nanoparticle size, shape and surface chemistry in oral drug delivery.
Amrita Banerjee (2016)
Recent progress in tumor pH targeting nanotechnology.
E. Lee (2008)
Lung cancer: epidemiology, etiology, and prevention.
C. D. Dela Cruz (2011)
Modified Panax ginseng Extract Inhibits uPAR-Mediated α[Formula: see text]β1-Integrin Signaling by Modulating Caveolin-1 to Induce Early Apoptosis in Lung Cancer Cells.
I. Hwang (2016)
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
S. Tan (2017)
Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer.
Guo-bin Xu (2018)
Cytotoxicity and antibacterial activity of gold-supported cerium oxide nanoparticles
K. Suresh Babu (2014)
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
M. Persson (2014)
A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants
A. Xu (2012)
Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
P. Tarighi (2015)
This paper is referenced by
Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine
Y. Hong (2020)
Dextran-Curcumin Nanoparticles as a Methotrexate Delivery Vehicle: A Step Forward in Breast Cancer Combination Therapy
M. Curcio (2019)
Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.
Chen Cheng (2020)
Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix
A. Kowalczyk (2020)
Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
Na Yin (2020)
Versatile role of curcumin and its derivatives in lung cancer therapy
M. Ashrafizadeh (2020)
Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin.
Shenghu Guo (2019)
Analysis of toxicity and anticancer activity of micelles of sodium alginate-curcumin
Alicja Karabasz (2019)
Expression of ATP/GTP Binding Protein 1 Has Prognostic Value for the Clinical Outcomes in Non-Small Cell Lung Carcinoma
Hee Jeong Kwak (2020)
Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.
Hasnat Tariq (2020)
Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers
He Bao (2020)
Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
G. Zheng (2019)
CD44-targeted hyaluronic acid–curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways
L. Diao (2019)
Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs
S. Alven (2020)
Impact of pH and cell medium on the interaction of doxorubicin with lipoic acid cyclodextrin conjugate as the drug carrier
Olga Swiech (2020)
Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment.
H. Ye (2020)
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
Qingxia Fu (2020)
Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers
Yonglong Jin (2020)
Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
T. N. Pham (2019)
Design of Functional Polymeric Nanoparticles for Biomedical Applications
Heba Asem (2020)
Cytotoxic effects of chemopreventive agents curcumin, naringin and epigallocathecin-3-gallate in C2C12 myoblast cells
E. P. Septisetyani (2020)
Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Sara S. Bashraheel (2020)